Answers are grounded in this paper and cite their sources.
Patients in remission/LDA receiving baricitinib are more likely to achieve pain control than patients receiving TNFi/OMA.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: